In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature
- PMID: 15456349
In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature
Abstract
The echinocandins anidulafungin and micafungin and the triazole posaconazole are currently undergoing phase III clinical trials. Caspofungin and voriconazole have recently been licensed for the treatment of aspergillosis (both agents), other less common mould (voriconazole) and candidal (caspofungin) infections. This review summarizes the published in vitro data obtained by NCCLS or NCCLS modified methods on the in vitro fungistatic and fungicidal activities of these five agents for yeasts and moulds in comparison to the established agents, amphotericin B, fluconazole, itraconazole, and flucytosine. Among the yeasts, the echinocandins have less activity for Candida parapsilosis and Candida guilliermondii, no activity for Cryptococcus neoformans and Trichosporon spp., but good fungistatic and fungicidal activity in vivo and in vitro for most of the other Candida spp.; this fungicidal activity has been reported by minimum fungicidal concentrations (MFCs) or time kill curve results. The new triazoles exhibit good fungistatic activity (but not fungicidal) for most Candida spp., C. neoformans, and Trichosporon spp. For the Aspergillus spp. evaluated, the echinocandins have similar or better fungistatic activity than those of amphotericin B and the triazoles, but fungicidal activity has been demonstrated only with amphotericin B and the triazoles, with the exception of fluconazole. Most studies showed posaconazole and voriconazole minimum inhibitory concentrations (MICs) ranging from 0.25 to 8 microg/ml for non-solani Fusarium spp., while MIC and minimum effective concentration (MEC) endpoints of the echinocandins were >8 microg/ml. The fungistatic activity of the triazoles is also superior to that of the echinocandins for most of the dimorphic fungi and the Zygomycetes. However, micafungin has activity for the mould phase of most dimorphic fungi, but not for the parasitic or yeast phase of Paracoccidioides brasiliensis. The echinocandins appear to have variable and species dependent fungistatic activity for the dematiaceous fungi, but all agents have poor or no activity against most isolates of Scedosporium prolificans. Only amphotericin B exhibit good fungistatic activity against the Zygomycetes. The combination of caspofungin with some triazoles, amphotericin B or liposomal amphotericin B has been synergistic in vitro, in animal models and in patients. Breakpoints are not available for any mould and antifungal agent combination. In vitro/in vivo correlations should aid in the interpretation of these results, but standard testing conditions are needed for the echinocandins, especially for mould testing, to obtain reliable results.
Similar articles
-
New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.Expert Rev Anti Infect Ther. 2009 Oct;7(8):981-98. doi: 10.1586/eri.09.67. Expert Rev Anti Infect Ther. 2009. PMID: 19803707 Review.
-
Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.Antimicrob Agents Chemother. 2006 Mar;50(3):917-21. doi: 10.1128/AAC.50.3.917-921.2006. Antimicrob Agents Chemother. 2006. PMID: 16495251 Free PMC article.
-
In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature.Mycopathologia. 2001;150(3):101-15. doi: 10.1023/a:1010954803886. Mycopathologia. 2001. PMID: 11469757 Review.
-
In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.J Clin Microbiol. 2001 Mar;39(3):954-8. doi: 10.1128/JCM.39.3.954-958.2001. J Clin Microbiol. 2001. PMID: 11230410 Free PMC article.
-
Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.J Clin Microbiol. 1998 Oct;36(10):2950-6. doi: 10.1128/JCM.36.10.2950-2956.1998. J Clin Microbiol. 1998. PMID: 9738049 Free PMC article.
Cited by
-
Clinical utility of fungal culture and antifungal susceptibility in cats and dogs with histoplasmosis.J Vet Intern Med. 2023 May-Jun;37(3):998-1006. doi: 10.1111/jvim.16725. Epub 2023 Apr 24. J Vet Intern Med. 2023. PMID: 37092675 Free PMC article.
-
Fungal arthritis: A challenging clinical entity.World J Orthop. 2023 Feb 18;14(2):55-63. doi: 10.5312/wjo.v14.i2.55. eCollection 2023 Feb 18. World J Orthop. 2023. PMID: 36844378 Free PMC article. Review.
-
Systemic Antifungal Therapy for Invasive Pulmonary Infections.J Fungi (Basel). 2023 Jan 21;9(2):144. doi: 10.3390/jof9020144. J Fungi (Basel). 2023. PMID: 36836260 Free PMC article. Review.
-
Antifungal Susceptibility Testing: A Primer for Clinicians.Open Forum Infect Dis. 2021 Sep 9;8(11):ofab444. doi: 10.1093/ofid/ofab444. eCollection 2021 Nov. Open Forum Infect Dis. 2021. PMID: 34778489 Free PMC article. Review.
-
Fungal keratitis: Mechanisms of infection and management strategies.Surv Ophthalmol. 2022 May-Jun;67(3):758-769. doi: 10.1016/j.survophthal.2021.08.002. Epub 2021 Aug 20. Surv Ophthalmol. 2022. PMID: 34425126 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous